Jupiter Asset Management Ltd. purchased a new stake in Insulet Co. (NASDAQ:PODD – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The firm purchased 22,306 shares of the medical instruments supplier’s stock, valued at approximately $6,431,000.
Other hedge funds have also added to or reduced their stakes in the company. Ethic Inc. lifted its stake in Insulet by 30.3% in the first quarter. Ethic Inc. now owns 2,530 shares of the medical instruments supplier’s stock valued at $807,000 after buying an additional 589 shares during the period. Private Advisor Group LLC acquired a new position in Insulet in the first quarter valued at about $468,000. Rhumbline Advisers lifted its stake in Insulet by 78.8% in the first quarter. Rhumbline Advisers now owns 151,577 shares of the medical instruments supplier’s stock valued at $48,347,000 after buying an additional 66,814 shares during the period. Retirement Systems of Alabama acquired a new position in Insulet in the first quarter valued at about $6,547,000. Finally, Ontario Teachers Pension Plan Board acquired a new position in Insulet in the first quarter valued at about $249,000.
Insulet Stock Down 0.4 %
PODD stock opened at $174.06 on Friday. The company has a quick ratio of 2.35, a current ratio of 3.26 and a debt-to-equity ratio of 2.26. The business has a 50 day moving average price of $153.90 and a two-hundred day moving average price of $227.20. The company has a market cap of $12.15 billion, a price-to-earnings ratio of 101.79, a P/E/G ratio of 2.34 and a beta of 0.83. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $335.91.
Insider Buying and Selling at Insulet
Analysts Set New Price Targets
Several research firms have weighed in on PODD. Morgan Stanley cut their target price on Insulet from $208.00 to $185.00 and set an “equal weight” rating on the stock in a research note on Friday, September 29th. JPMorgan Chase & Co. dropped their price target on Insulet from $325.00 to $162.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 17th. Bank of America dropped their price target on Insulet from $365.00 to $295.00 and set a “buy” rating on the stock in a research report on Thursday, August 24th. SVB Leerink started coverage on Insulet in a research report on Monday, October 16th. They set an “outperform” rating and a $184.00 price target on the stock. Finally, Wells Fargo & Company dropped their price target on Insulet from $375.00 to $330.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 9th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $254.80.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.
- Five stocks we like better than Insulet
- What Are MATANA Stocks?
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Options Trading – Understanding Strike Price
- MarketBeat Week in Review – 11/13 – 11/17
- How to Invest in Communication Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.